Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development

Prostate

Volumn 64, Issue 1, 2005, Pages 92-100

  Ishiguro, Hitoshi ^a   Nakaigawa, Noboru ^a   Miyoshi, Yasuhide ^a   Fujinami, Kiyoshi ^a   Kubota, Yoshinobu ^a   Uemura, Hiroji ^a,b  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Amphoterin; Invasion; Prostate cancer; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; HIGH MOBILITY GROUP B1 PROTEIN; HORMONE; LIGAND; MESSENGER RNA; RECEPTOR PROTEIN;

AGING; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; FORMAZANS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; LIGANDS; MALE; NEOPLASM INVASIVENESS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLIUM SALTS;

EID: 19544381056     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20219     Document Type: Article

References (27)

1. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000;42:150-160.
2. Grossman ME, Huang H, Tindall DJ. Androgen signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93: 1687-1697.
3. Fujinami K, Uemura H, Ishiguro H, Kubota Y. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP. Int J Mol Med 2002;10:173-176.
4. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 1995;27:314-320.
5. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin Cancer Res 2002;8:775-781.
6. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer: A possible of tyrosine kinase inhibition of growth factor. Mol Cancer Ther 2003;2:1139-1147.
7. Ikeda N, Uemura H, Ishiguro H, Hori M, Hosaka M, Kyo S, Miyamoto K, Takeda E, Kubota Y. Combination treatment with 1alpha, 25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther 2003;2:739-746.
8. Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, Kitamura H, Kubota Y. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003;56:280-286.
9. Ishiguro H, Uemura H, Fujinami K, Ikeda N, Ohta S, Kubota Y. 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. Int J Cancer 2003;105:26-32.
10. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001;44:129-146.
11. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YCE, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-15004.
12. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clause M, Wang F, Pan YE, Tsang TC, Stern D. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992;267:14987-14997.
13. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, Morser J, Stern D, Schmidt AM. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 1995;270:25752-25761.
14. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-691.
15. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
16. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, Rauvala H. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993;268:19726-19738.
17. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-360.
18. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-170.
19. Miki S, Kawayama S, Miki Y, Nakamura Y, Yamamoto M, Sato B, Kishimoto T. Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro. Biochem Biophys Res Commun 1992;196:984-989.
20. Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H. Advanced glycation end products-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun 1996;222:700-705.
21. Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001;48:1577-1578.
22. Schraml P, Bendik I, Ludwig CU. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res 1997;57:3669-3671.
23. Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 2000;59:1094-1105.
24. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003;10:1863-1868.
25. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272:8723-8730.
26. Katori H, Baba Y, Imagawa Y, Nishimura G, Kagesato Y, Takagi E, Ishii A, Yanoma S, Maekawa R, Yoshioka T, Nagashima Y, Kato Y, Tsukuda M. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Let 2002;178:151-159.
27. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-25790.